New Ray Medicine International Holding Ltd
06108
Company Profile
Business description
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
Contact
19 Dangui Road
B-C, 37th Floor, Dikai International Center
Hangzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Pharmaceutical Retailers
Fiscal Year End
31 December 2025
Employees
29
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,999.00 | 16.40 | -0.18% |
| CAC 40 | 7,837.78 | 24.18 | -0.31% |
| DAX 40 | 24,240.57 | 21.65 | -0.09% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,172.82 | 35.88 | 0.39% |
| HKSE | 24,773.33 | 403.60 | -1.60% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
| NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
| SSE Composite Index | 3,573.21 | 42.51 | -1.18% |